Sort
10,766 grants matching “checkpoint inhibitor”
Inhibition of Stromal-Derived DKK3 to Enhance the Response of Pancreatic Cancer to Immunotherapy
$208,800Rosa F. Hwang · University Of Tx Md Anderson Can Ctr · R21 · FY2017 · CA
Target metabolic vulnerabilities of MDSCs to enhance cancer immunotherapy
$208,581Bin Zheng · Massachusetts General Hospital · R21 · FY2019 · CA
Extracellular Vesicle Core
$208,547Sicheng Wen · Rhode Island Hospital · P30 · FY2024 · GM
A novel gene-based immunotherapy inducing melanoma destruction
$208,281Katja Michael · University Of Texas El Paso · R21 · FY2025 · CA
Modeling Dynamic Immune Cell Modulation in a 3-D Tissue Engineered Platform to Enhance Patient-specific Immunotherapy for Lung Cancer
$208,271Jessy Satyadas Deshane · University Of Alabama At Birmingham · R21 · FY2022 · CA
Determining the impact of ancestry on oropharyngeal cancer biology and treatment response.
$208,164Vlad C Sandulache · Baylor College Of Medicine · R21 · FY2024 · DE
Developing a novel therapeutic strategy for overcoming resistance to PD-1 blockade in Triple-negative breast cancer
$208,038Chunyan Zhang · Beckman Research Institute/City Of Hope · R21 · FY2024 · CA
Engineering class I MHC molecules to drive enhanced anti-cancer responses
$207,898David M Kranz · University Of Illinois At Urbana-Champaign · R21 · FY2022 · CA
BUBR1 in the Spindle Checkpoint and Tumor Suppression
$207,885New York Medical College · R01 · FY2001 · CA
THE ROLE OF GADD45 IN G2 - M CHECKPOINT
$207,866University Of Pittsburgh At Pittsburgh · R01 · FY2000 · CA
TARGETING ORIGINS OF REPLICATION WITH CANCER DRUGS
$207,741Roswell Park Cancer Institute Corp · R01 · FY2000 · CA
Targeting the DNA Damage Response in CDK12-Mutant Prostate Cancer
$207,673Kent W Mouw · Dana-Farber Cancer Inst · R21 · FY2021 · CA
E2F AND THE CONTROL OF APOPTOSIS
$207,402Ohio State University · R01 · FY2001 · CA
CYTOKINE SIGNALING PATHWAYS REGULATING A G1 CHECKPOINT
$207,321University Of Iowa · R01 · FY2003 · CA
Flow Cytometry Core
$206,871W Martin Kast · University Of Southern California · P30 · FY2024 · CA
A Strategy for Reactivating p53 in Cancer Stem Cells Using a Novel HdmX Inhibitor
$206,843Mark W Jackson · Case Western Reserve University · R21 · FY2013 · CA
Distinguishing inflammatory Th17 subsets through using an autoimmune Th17-selective inhibitor
$206,770Zhiheng He · University Of Southern California · R21 · FY2023 · AI
HDAC6-Selective Inhibitors for Pancreatic Cancer Treatment
$206,721Werner Tueckmantel · Psychogenics, Inc. · R43 · FY2008 · CA
Radiation-induced targeted extracellular vesicles -based gene delivery for glioma therapy
$206,600Bakhos A. Tannous · Massachusetts General Hospital · R21 · FY2021 · NS
RADIATION INDUCED G1 CHECKPOINT ARREST IN YEAST
$206,560University Of Chicago · R01 · FY2002 · GM
Quantitative PET Imaging for Oncologic Immune Response Prediction
$206,408Benjamin M Larimer · University Of Alabama At Birmingham · R00 · FY2020 · CA
FORMATION, INTERACTION &FUNCTION OF SPINDLE COMPONENTS
$206,392Wadsworth Center · R01 · FY2000 · GM
Mechanisms of improved organ function following sepsis treatment with vitamin c, thiamine and hydrocortisone (triple therapy)
$206,250Daniel G. Remick · Boston University Medical Campus · R21 · FY2021 · AI
Endogenous and Environmental AHR Ligands in Head and Neck Cancer Aggression and Immunosuppression
$206,250David H Sherr · Boston University Medical Campus · R21 · FY2020 · ES
Adaptive signaling exposes a therapeutic vulnerability in NRAS melanomas
$206,190Michael J Weber · University Of Virginia · R21 · FY2014 · CA